Table 2 Dose effect of glucagon-like peptide 1. Effects of graded doses of GLP-1 and usual insulin before breakfast in volunteers with type 1 diabetes with no endogenous insulin secretion, with number of subjects studied at each dose. Time-averaged incremental (delta) responses (area under the curve divided by total time) of plasma glucose through 3 hours, pancreatic polypeptide(HPP), 0 to 30 min, and glucagon, 0 to 60 min, mean ± se. Polynomial regression analysis (R2) for dose vs incremental responses.
From: Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
Dose μg/kg | n | Glucose mmol/l | HPP pmol/l | Glucagon ng/l |
|---|---|---|---|---|
0 | 15 | 6.5 ± 0.8 | 27.4 ± 4.6 | 11.9 ± 3.7 |
0.32 | 9 | 5.8 ± 1.7 | 14.1 ± 6.4 | 8.5 ± 4.5 |
0.63 | 12 | 5.2 ± 0.8 | 3.1 ± 2.2 | 6.6 ± 2.5 |
1.25 | 11 | 4.7 ± 0.8 | 1.7 ± 0.89 | 5.1 ± 6.7 |
R2 | 0.99 | 0.99 |